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IntroductIon: Pre-pregnancy overweight and obesity have been proposed as 
risk factor to diabetes and hypertension during pregnancy. These medical com-
plications enhance the economic burden related to attend the pregnancy when 
it is classified as high risk pregnancy. objectIves: Identify diseases related to 
pre-gestational overweight and obesity in women with high risk pregnancy and 
estimate the economic burden to attend high risk pregnancy compared with nor-
mal pregnancy Methods: Were studied 600 patients with high risk pregnancy to 
identify pre-pregnancy overweight and obesity and were estimated the cost related 
to the medical health care during pregnancy. Were calculated: mean, standard 
deviation, median, percentilar values, logistic regression and Odds Ratio with 
95% confidence interval. Were estimated costs for a hypothetical group of 600 
women with normal pregnancy, using Monte Carlo simulation method to compare 
economic burden between high risk pregnancy and normal pregnancy. Statistical 
differences were calculated with Student T test to paired samples. Groups were 
paired by maternal age and gestational age. results: Pre-pregnancy body mass 
index mean was 29.59 (±6.42)kg/m2. The obesity was a risk factor to develop ges-
tational diabetes (OR: 1.95; IC95%: 1.39 to 2.76; p= 0.000). Were estimated in USD, 
to following costs: mean cost for prenatal health care: [$165.28 (±$52.39) in nor-
mal pregnancy; $801.18 (±$272.14), for high risk pregnancy, p= 0.000], mean cost 
for laboratory test [$ 138.41 (±$32.12) normal pregnancy; $895.91 (±$304.32) high 
risk pregnancy (p= 0.000)], delivery cost [$748.39 (±$340.51) normal pregnancy; 
$1,762.60 (±$513.88), p= 0.000 high risk pregnacy] and mean total cost $2,514.86 
(±$852.57), in normal pregnancy and $6,800.34 (±$3,829.82) high risk pregnancy 
(p= 0.000). conclusIons: 75% pregnant women reach the pregnancy with preges-
tational overweight or obesity, and these conditions are risk factor to medical 
complications during pregnancy with significant higher costs derived from health 
care during pregnancy respect to women with normal pregnancy without pre-
pregnancy overweight or obesity
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objectIves: To compute the annual cost of FDC drugs used in the treatment of 
Type2 Diabetes Mellitus (T2DM) and study the variation in the costs. Methods: 
Indian Council of Medical Research (ICMR) and International Diabetes Federation 
(IDF) guidelines were used to understand the treatment of T2DM. Current Index of 
Medical Specialities (CIMS) Oct- Jan 2015 issue and Indian Drug Review (IDR) issue 
1, Jan 2015 were used to capture the prices of medicines available in the Indian 
market. The annual cost of treatment and variation in the annual cost of drugs was 
studied. results: Recommended first line FDC according to International Diabetes 
Federation is metformin + sulfonylurea. If we initiated the treatment with met-
formin + glimepiride (500mg + 1mg) OD, then annual cost of treatment was found 
to be Rs.438-2744. A maximum variation of 533% was noted in the least-highest cost 
of treatment. A minimum of 1% variation was observed for metformin + glipizide 
(2.5mg + 400mg) OD, among combination therapy in its least-highest cost of treat-
ment. Likewise, if the treatment is initiated with other combination therapy, say 
metformin + pioglitazone (500mg +15mg) BD, then annual cost of treatment was 
found to be Rs.1387-6935. This showed a maximum variation of 665% in its least-
highest cost of treatment. On the other hand metformin + voglibose (500 + 0.3mg) 
combination showed a minimum price variation of 86% only. conclusIons: It was 
concluded that a maximum of 6 fold variation was observed in the least-highest 
costs of treatment with metformin + voglibose (500mg + 0.3mg). A wide varia-
tion exist in the minimum and maximum price of anti-diabetic FDC manufactured 
across the different brands available in the Indian market.
PDB31
eConomiC AsPeCts in the mAnAgement of DiABetes in itAly
Marcellusi A1, Viti R2, Sciattella P2, Aimaretti G3, De Cosmo S4, Provenzano V5, Tonolo G6, 
Mennini FS1
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation 
and HTA (EEHTA), University of Rome, Rome, Italy, 2University of Rome “Tor Vergata” Italy, Rome, 
Italy, 3University of Eastern Piedmont, Vercelli, Italy, 4“Casa Sollievo della Sofferenza” Hospital, 
San Giovanni Rotondo, Italy, 5Hospital of Partinico, Palermo, Italy, 6ASL Olbia, Olbia, Italy
objectIves: Diabetes Mellitus (DM) is a chronic-degenerative disease associated 
with a high risk of chronic complications and co-morbidities. The aim of this study 
is to estimate the average annual cost incurred by the National Health Service 
(NHS) for the treatment of DM stratified by patients’ comorbidities. Moreover, the 
model estimate the economic impact implementing good clinical practice for the 
management of diabetic patients. Methods: Data were extrapolated from admin-
istrative database of the Marche Region and specific inclusion and exclusion criteria 
were developed from clinical board in order to estimate patients with DM only, 
DM+1, DM+2, DM+3 and DM+4 comorbidities (cardiovascular disease, neuropathy, 
nephropathy and retinopathy). Regional data were considered a good proxy for 
implementing a previous developed Cost of Illness model from NHS perspective 
already published. Scenario analysis were considered to estimate the economic 
impact of good clinical practice implementation in the treatment of DM and its 
comorbidities in Italy. results: The model estimated an average number of dia-
betic patients per year in the Marche region of 86.155 (5.5% of population) from 
2008-2011. Mean costs per patients with DM only, DM+1, DM+2, DM+3 and DM+4 
comorbidities were € 179, € 1,560, € 2,736, € 8,494 and € 21,321, respectively. From the 
NHS perspective, the total economic burden of DM in Italy amounted to € 8.5 billion/
year (22% for drugs, 74% for hospitalization and 4% for visits). Scenario analysis 
demonstrate that implementation of good clinical practice could save over € 700 
million year. conclusIons: This model is the first study that consider real world 
data and CoI model to estimate the economic burden of DM and its comorbidities 
from the NHS perspective. Integrated management of the diabetic patient could be 
a good driver for the reduction of the costs of this disease in Italy.
4,282 saxagliptin and 1,286 linagliptin) and 3,229 patients with Commercial coverage 
(2,368 sitagliptin; 643 saxagliptin and 218 linagliptin). Patient demographics were 
similar for index medications: Medicare cohort – mean age 70-72; female 50-52% 
Commercial cohort – mean age 55-56; female 44%. Patients on linagliptin showed 
a higher co-morbidity level at baseline (Medicare DCSI = 3.0 vs 2.4/2.2; Commercial 
DCSI = 1.2 vs. 0.9/0.9), higher use of pre-index insulin (Medicare 22% vs 15%/14%; 
Commercial 18% vs 11%/10%) and higher pre-index costs (Medicare mean $14,448 vs 
$11,818/$10,399; Commercial mean $13,868 vs $9,357/$8,223) than sitagliptin or saxa-
gliptin cohorts, respectively. When controlling for other factors, post-index costs were 
similar between the medication cohorts - Medicare: sitagliptin $13,913; saxagliptin 
$13,651; linagliptin $13,859; Commercial: sitagliptin $11,677; saxagliptin$12,059; lina-
gliptin $11,163. conclusIons: For Medicare and Commercial populations, members 
on linagliptin may have been more complex patients (higher DCSI, more use of insulin, 
higher pre-index costs). When controlling for baseline factors, 12-month post-index 
direct medical costs were similar between index DPP4 medications.
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objectIves: to compare the healthcare utilization and costs in the year before and 
after randomization among participants of a clinical trial assessing the effective-
ness of nurse-led telecoaching in optimizing diabetes control in Belgium. Methods: 
Patients were affiliates of the Independent Sickness Funds with type 2 diabetes 
selected by hypoglycaemic agent consumption, invited into the study and randomized 
to telecoaching or usual care. The intervention was delivered by diabetes educators 
in five telephone sessions spread over 6 months. Costs of the intervention were col-
lected along the trial. Information on resource utilization was extracted from the 
database of the sickness funds and the between group difference in change was 
analyzed per service category. results: 287 patients enrolled in the intervention 
and 287 in the control group. The average cost of the intervention was € 300.64. At 
baseline, the annual mean healthcare cost (CI) was € 5,543 (4,410–6,677) in the inter-
vention and € 4,101 (3,375–4,827) in the control group and in the year of the trial € 5,516 
(4,630 –6,402) and 4,757 (3,892–5,622), implying a change of -1% and +16% respectively. 
Hospitalizations affected 19% and 15% of patients in the intervention and control 
group, accounting for 33% and 23% of total costs at baseline, respectively. In the year 
of the trial, changes were observed in the intervention and control group respec-
tively in the number of hospital admissions: -27% and +36% (p= .048), endocrinologist 
consultations: +35% and -10% (p= .023), HbA1c tests: +9% and -12% (p< .0001), lipid 
tests: +8% and -16% (p< .0001) and consumption of lipid modifying agents: +14% and 
+1% (p= .042). conclusIons: Participants of the nurse-led telecoaching program 
aimed at improvement of diabetes selfmanagement demonstrated increased costs for 
guideline recommended outpatient care and a decrease in the number and costs of 
hospital admissions compared to controls. These findings are hypothesis generating.
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objectIves: To compare drug acquisition costs and most commonly used doses 
between two GLP-1 agonists, once-weekly exenatide (QW) 2.0 mg with no dose titra-
tion, and once-daily liraglutide with a recommended starting dose of 0.6 mg and 
titration to 1.2 mg or 1.8 mg over 2-weeks. Methods: This cohort study included 
patients with type 2 diabetes initiating exenatide QW or liraglutide between Jan 2012 
and Feb 2014, who had > 6-months of preceding coverage in U.S. healthcare claims 
database. During the 6 months following treatment initiation, drugs dispensed and 
associated pharmacy costs were compared between exenatide QW 2 mg dose and 
liraglutide dose subgroups, defined by maintenance dose at 60 days. results: The 
exenatide QW (N= 3,217) and liraglutide (N= 10,954) cohorts had comparable charac-
teristics at baseline. Due to titration recommendations, the majority of the liraglu-
tide patients received 1.8 mg per day dose (56.2%), while 2.2% and 41.6% received 0.6 
mg and 1.2 mg per day, respectively, by the end of follow-up. Comparing costs asso-
ciated with exenatide QW versus specific liraglutide maintenance doses, patients 
on liraglutide 1.8 mg per day had higher average pharmacy costs of $3,827 (95%CI: 
$3,752-$3,902) compared to exenatide QW costs of $3,556 (95% CI: $3,462-$3,649), and 
higher average pharmacy costs associated with all antihyperglycemic drug dispens-
ings, $2,543 (95%CI: $2,502 - $2,585), compared to exenatide QW costs $2,345 (95%CI: 
$2,290 - $2,401). conclusIons: Exenatide QW, which does not require titration, 
provided savings in both overall pharmacy costs and costs of antihyperglycemic 
drugs compared to the majority (56.2%) of liraglutide patients who required titration 
to the highest dose of 1.8 mg. Lower pharmacy costs in addition to overall safety 
and efficacy profile, convenience of no titration, and once weekly dosing, provide a 
good cost-benefit value for patients treated with exenatide QW.
PDB29
imPACt of overweight AnD oBesity in the frequenCy meDiCAl 
ComPliCAtions During PregnAnCy AnD eConomiC BurDen in the high 
risk PregnAnCy in mexiCo
Balderas-Peña L1, Sat-Muñoz D1, Ramirez-Conchas R1, Martínez -Herrera  B1,  
Cruz-Corona E1, Hernández-Higareda S2, Avalos-Nuñez J2, Chávez-Hurtado J3,  
Salcedo-Rocha A4, García de Alba-García J4
1UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, 
Jalisco, Mexico, 2UMAE Hospital de Gineco-Obstetricia Centro Médico Nacional de Occidente IMSS, 
Guadalajara, Jalisco, Mexico, 3Universidad de Guadalajara, Zapopan, Mexico, 4Delegación Jalisco 
IMSS, Guadalajara, Jalisco, Mexico
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A603
tion of all direct costs we determined that the total average cost of uncomplicated 
hypothyroidism during pregnancy and childbed per women was € 124.79. In the 
cost structure of health care provision for pregnant women with uncomplicated 
hypothyroidism the most significant costs are spent on thyroid laboratory tests.
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objectIves: Diabetes is a major economic burden disease globally. The geriatric 
diabetic cost economic studies in India are limited. Hence this study carried out 
with the objective to assess the various costs incurred during the geriatric dia-
betic treatment (COI model). Methods: This was a prospective, cross sectional 
study conducted from July 2012-July 2014 in the General Medicine Department of 
Kasturba Medical College Hospital, Manipal, after obtaining ethical clearance. Cost 
details were obtained from hospital finance and pharmacy. The Descriptive sta-
tistical method was applied results: A total of 475 cases were enrolled of which 
52.42% had diabetes. Of this, 27.71% had DM alone, 6.82 % had DM associated renal 
disease (i.e.: 3.6% were DMAKI, 3.2% were DMCKD), 12.44% had other than renal 
DM complications (microvascular), 48.19% had both DMHTN, 4.81% had DMHTN 
associated complications. The total cost incurred for the treatment of the disease 
and its related complications (DM alone, DMAKD, DMCKD, DM neurological compli-
cations, DMHTN & DMHTN) did not vary significantly [ I.e. Mean+ SD (INR): 16044.7 
+ 37740.06, 15374.51+ 11915.94, 14840.03+14124.05, 8395.35+ 16580.11, 27130.28 + 
64934.04, 14430.5+ 13113.78 ) . The cost of treatment (INR) appeared low due to vary-
ing factors like free screening or treatment for other symptoms, etc. The cost based 
on various factors were as listed - Medicine charge > Laboratory/diagnostic charges 
> Nursing charges > Material charges > Procedure charges > Professional charges 
> Admission related charges > Miscellaneous charges. conclusIons: This study 
clearly suggests that medicine expense is the highest cost factor in DM treatment. 
The second highest cost was laboratory followed by nursing costs. Research on 
pharmacoeconomic models like cost effective analysis (CEA), Cost minimization 
analysis (CMA), and Cost benefit analysis (CBA) by the pharmacist &the stakehold-
ers is essential to reduce the burden in geriatrics. Lack of availability of direct non-
medical cost was the limitation of this study
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objectIves: as a result of type II Diabetes Mellitus (T2DM), patient may develop sev-
eral complications, which cause serious economic burden to health care system. The 
objective of the study was to evaluate the treatment cost of T2DM in Estonia for 4 
serious complications: myocardial infarction (MI), stroke, nephropathy and retinopa-
thy during the year, when the event developed and a year later. Methods: anony-
mous data about T2DM patients´ treatment records was obtained from Estonian 
Health Insurance Fund for the years 2001-2011. The complications were defined 
by ICD-10 codes and following criteria were applied for the sample to be analysed: 
the complication had been detected first time between the years 2004-2008 (no 
complication during the preceding 3 years). The data did not include outpatient 
medication consumption. The control group consisted of randomly chosen T2DM 
patients, who did not have the complication during this time period. Data analy-
sis was performed using Stata 11. results: the overall sample consisted of 3016 
patients (age 45-69). Inpatient and outpatient treatment costs were calculated for 
MI, stroke, nephropathy and retinopathy for the year, when the event occurred, and 
for the year later. The highest treatment costs appeared during the year, when the 
event was recorded, and were for the MI 6,844, stroke 4,113, nephropathy 3,473 and 
retinopathy 598 EUR. A year later the costs were 1,860 (-73%), 2824 (-32%), 2490 (-29%) 
and 701 (+17) accordingly. conclusIons: MI and stroke are amongst highest costs 
during the first year and a year later the costs are lower, however for retinopathy 
the cost is higher than the first year. A year later, cost of stroke remains higher than 
MI, presumably due to follow-up care. The complication cost data obtained gives 
information about the healthcare expenditure in Estonia and can be used for cost-
effectiveness assessment for new diabetes medications.
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objectIves: The number of patients in the Czech Republic treated for diabetes in 
2013 was nearly 862 thousand. The Type 2 diabetes mellitus share was 91.7 %. The 
number of treated diabetics has been increasing in a long-term trend as well as 
the number of their chronic complications. The goal of the study is to estimate the 
cost of type 2 diabetes from the health insurance perspective in a newly established 
regional diabetology outpatient facility. Methods: The cost-of-illness analysis of 
the direct costs was performed from the third-party payer perspective based on 
data from the year 2014. The bottom-up approach was used. Data of all 552 patients 
with Type 2 diabetes were (all patients with Type 2 Diabetes in the ambulance) 
were taken into consideration. Altogether 1 696 consultations were provided to the 
patients during the particular year. results: The average cost of consultations for 
one type-2-diabetes patient per year was CZK 840.56 (~EUR 30.5), the average cost 
of treatment for one patient was CZK 10 336 (~EUR 375), the average material cost 
was CZK 2 835 (~EUR 103) per patient, and CZK 113.7 (~EUR 4) was the average cost 
for amputation per patient, and the average cost of diabetic nephropathy was CZK 
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objectIves: The aim of this study was to assess the indirect costs associated 
with types 1 diabetes mellitus (DM) from the perspective of the Social Insurance 
Institution (ZUS) in Poland. Methods: The estimates were based on data from 
the year 2013 concerning absence from work due to the illness (sick leave) the 
amount of short-term disability, the sufferers of which claim rehabilitation ben-
efit, and the amount of permanent (or long-term) disability, the sufferers of which 
claim disability pension. Cost analysis was performed based on the Human Capital 
Approach taking into account Gross Domestic Product (GDP) per capita equaled 10 
278 EUR. results: Total indirect costs of DM types 1 in the year 2013 in Poland 
were 80 148 008 EUR. Total indirect costs associated with absenteeism were 8 263 
EUR calculated using GDP per capita per patient. The highest component of indirect 
costs of DM type 1 was long-term disability, in particular unlimited period, which 
accounted for 71%. Long-term (limited period), short term disability and sick leave 
costs constitute 17%, 3% and 9% of total indirect costs of DM type 1, respectively. 
One sick leave of a person with types 1 diabetes generated a cost of lost productiv-
ity equal to 431 EUR. The cost of disability pension per one person was higher than 
rehabilitation benefit, and equalled 20 600 EUR (limited period) and 362 505 EUR 
(unlimited period) compared with 3 611 EUR. conclusIons: DM in Poland gener-
ated high indirect costs. The main component was long-term disability, in particular 
unlimited period; rehabilitation benefit and disability pension (limited period) and 
sick leave generated much lower costs for Social Insurance Institution.
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objectIves: This is the first study that assesses the economic costs of Type 1 
Diabetes Mellitus (T1DM) in pediatric patients in Spain. The main objective of this 
study was to estimate direct healthcare costs (DHC) and direct non-healthcare costs 
(DNHC) of T1DM in children and adolescents. Methods: CHRYSTAL (Costs and 
Health Related qualitY of life Study for Type 1 diAbetes meLlitus pediatric patients 
in Spain) is an observational study conducted in 2014 on a representative sample of 
275 patients aged 1-17 years diagnosed with T1DM, distributed across 12 hospitals 
in Spain. The study followed a bottom-up-approach to costing from a societal per-
spective. Data on demographic and clinical characteristics, health resource utiliza-
tion, and informal care were collected cross-sectionally from medical records and 
questionnaires completed by clinicians and patients´ caregivers. The reference year 
for unit prices was 2014. results: The average annual cost for a T1DM patient was 
€ 27,349. DHC amounted to € 4,144, with statistically significant differences depend-
ing on glycemic control (HbA1c < 7.5% versus HbA1c ≥ 7.5%): € 3,683 versus € 4,788 
(p< 0.05) and the existence of patient with acute and chronic complications (except 
hypoglycemia) and related comorbidities (with versus without): € 5,777 versus € 3,713 
(p< 0.05) after controlling for age and gender. The largest DHC were diabetes supplies 
(€ 2,035), outpatient visits (€ 841), and medication (€ 670). Average DNHC were € 23,204. 
Informal care (the time that caregivers spend in T1DM related caregiving tasks) 
represented 97.5% of DNHC (€ 22,618) and 82.7% of total costs. conclusIons: T1DM 
in children and adolescent patients carries a considerable social economic burden, 
especially in terms of informal care, which accounts for the largest proportion of 
total costs associated to the disease. The results shed light on the allocation of 
T1DM related resources, and might enlighten T1DM policy priority setting in Spain.
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bAckground: Hypothyroidism is a common disease during pregnancy with 
important medical and social significance. However, there is no real study eval-
uating the economic analysis of this pathology during pregnancy and childbed 
in Czech Republic. objectIves: To determine the real medical cost associated 
with uncomplicated hypothyroidism during pregnancy and childbed in Czech 
Republic. Methods: The 10 years retrospective non-randomized cross-sectional 
study was performed in 172 pregnant women with hypothyroidism with uncom-
plicated disease course who were followed and examined according to the rec-
ommendation of the guidelines of American Thyroid Association. The study was 
performed in the settings of Departments of Endocrinology of a university hospital 
and with laboratory assessment in a single center. We assessed serum concentra-
tions of thyroid hormones and finally, we calculated the cost of illness to estimate 
the cost of health care for uncomplicated hypothyroidism during pregnancy and 
childbed. results: Of the 172 positively screened women in the first trimester, 112 
(65.12%) had subclinical hypothyroidism and 40 (34.88%) had overt hypothyroidism. 
Seventy (40.7%) had already been treated for hypothyroidism before inclusion in 
the study and 102 (59.3%) were newly diagnosed. The median dose of levothyroxine 
was 58.83ug/day (range: 0-174) and median frequency of laboratory and medical 
check-up was 4.5 (range 3-6). The total average annual cost of laboratory tests was 
€ 852.91, the cost of entrance endocrine examination € 229.02, follow-up endocrine 
examination € 364.92 and levothyroxine therapy € 105.65. The total average cost of 
first medical and laboratory check-up during pregnancy per women was € 34.67 and 
of one follow-up examination € 17.67 per women. conclusIons: After calcula-
